Paul Aubert Net Worth

Paul Aubert biography

Paul D. Aubert J.D. serves as Independent Director of the Company. Mr. Aubert is currently Senior Vice President & General Counsel of Anthem Holdings Company and its subsidiaries, positions he has held since March 2018. From June 2014 to March 2018, he practiced law in a solo law practice and also served as part-time General Counsel to his current employers. From February 2012 through May 2014, Mr. Aubert served as General Counsel of Pernix Therapeutics Holdings, Inc., a Nasdaq-listed specialty pharmaceutical company. Before that, he was a Shareholder in the Corporate and Securities practice group at Winstead PC, a national law firm headquartered in Dallas, Texas, from 2007 to 2012. Mr. Aubert also served as an attorney in the Corporate and Securities practice groups of several national and international law firms prior to joining Winstead in 2004, including at Andrews Kurth LLP from 1999 to 2004, Weil, Gotshal & Manges LLP from 1998 to 1999 and Jones Walker LLP from 1996 to 1998. Mr. Aubert holds a Juris Doctor and an M.B.A. from Tulane University in New Orleans, Louisiana and a B.A. in History from Louisiana State University - Baton Rouge.

How old is Paul Aubert?

Paul Aubert is 50, he's been the Independent Director of Bio-Path Inc since 2018. There are 5 older and 1 younger executives at Bio-Path Inc. The oldest executive at Bio-Path Holdings Inc is Peter H. Nielsen MBA, 72, who is the Co-Founder, Chairman, CEO, Pres, CFO & Treasurer.

What's Paul Aubert's mailing address?

Paul's mailing address filed with the SEC is 4710 Bellaire Blvd #210, Bellaire, TX 77401, USA.

Insiders trading at Bio-Path Inc

Over the last 16 years, insiders at Bio-Path Inc have traded over $171,456 worth of Bio-Path Inc stock and bought 1,226,067 units worth $451,466 . The most active insiders traders include Capital, Llc Armistice Capi..., Thomas E Garrison e Michael J. Garrison. On average, Bio-Path Inc executives and independent directors trade stock every 423 days with the average trade being worth of $156,477. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 18 January 2019, trading 64,457 units of BPTH stock currently worth $171,456.

What does Bio-Path Inc do?

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen

Bio-Path Inc executives and stock owners

Bio-Path Inc executives and other stock owners filed with the SEC include:

• Peter Nielsen,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
• Peter H. Nielsen MBA,
  Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
• Douglas Morris,
  Director, Secretary, Director of Investor Relations
• Douglas P. Morris,
  Co-Founder, Director of Investor Relations, Sec. & Director
• Martina Molsbergen,
  Independent Director
• Heath Cleaver,
  Independent Director
• Paul Aubert,
  Independent Director
• Victoria Lake Rac,
  Regulatory Consultant
• Dr. Jeffery Lancet M.D.,
  Consultant
• Dr. Thomas A. Walker Ph.D.,
  Consultant
• Dr. Alan MacKenzie Ph.D.,
  Consultant
• Dr. Ana Tari Ashizawa Ph.D., MBA,
  Sr. VP of Research, Devel. & Clinical Design
• Anthony Price,
  Sr. VP of Fin., Accounting & Admin.
• Amy Sing,
  Director
• Ulrich W. Mueller,
  Chief Operating Officer
• Michael J. Garrison,
  Director
• Mark P Colonnese,
  Director
• Capital, Llc Armistice Capi...,
  
• Gillian C Ivers Read,
  Director
• Thomas E Garrison,
  Director
• Aline Sherwood,
  Director